Linsitinib: all 26 studies that test it
Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)RecruitingNCT07753603Phase 3
- Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)RecruitingNCT06112340Phase 2/3
- A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)CompletedNCT05276063Phase 2/3Results posted
- Eurosarc Trial of Linsitinib in Advanced Ewing SarcomaCompletedNCT02546544Phase 2Results posted
- A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple MyelomaTerminatedNCT01672736Phase 1/2Results posted
- Linsitinib in Treating Patients With Gastrointestinal Stromal TumorsCompletedNCT01560260Phase 2Results posted
- Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate CancerCompletedNCT01533246Phase 2Results posted
- Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung CancerCompletedNCT01533181Phase 2Results posted
- A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular CancerTerminatedNCT01334710Phase 2Results posted
- Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast CancerTerminatedNCT01205685Phase 2Results posted
- Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal CancerCompletedNCT01154335Phase 1Results posted
- A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib TrialCompletedNCT02057380Phase 2
- OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the PancreasWithdrawnNCT01600807Phase 1/2
- A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor MalignanciesWithdrawnNCT01567384Phase 1
- A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the BodyCompletedNCT01529684Phase 1
- Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)WithdrawnNCT01465815Phase 1/2
- Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)WithdrawnNCT01427205Phase 2
- Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) GeneCompletedNCT01221077Phase 2
- Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based ChemotherapyCompletedNCT01186861Phase 2
- A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCCTerminatedNCT01101906Phase 2
- OSI-906 and Irinotecan in Patients With Advanced CancerTerminatedNCT01016860Phase 1
- A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical CarcinomaCompletedNCT00924989Phase 3
- A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)CompletedNCT00889382Phase 1/2
- A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)CompletedNCT00739453Phase 1
- Study of Intermittent OSI-906 DosingCompletedNCT00514306Phase 1
- Study of Continuous OSI-906 DosingCompletedNCT00514007Phase 1